By Fineline Cube 
GE HealthCare (NASDAQ: GEHC) reported fourth‑quarter 2025 revenue of USD 5.7 billion, up 7.1% year‑on‑year (YOY), bringing full‑year revenue to USD 20.6 billion, a 4.8% YOY increase. Strong performance in Pharmaceutical Diagnostics and Imaging segments offset softness in Patient Care Solutions, while strategic acquisitions and upcoming Intelerad purchase position the company for cloud‑enabled growth.
Financial Performance Summary
| Metric | Q4 2025 | Full‑Year 2025 | YOY Growth |
|---|---|---|---|
| Total Revenue | USD 5.7 B | USD 20.6 B | +4.8% |
| Gross Profit | USD 2.3 B | USD 8.2 B | — |
Segment Performance (Q4 2025)
| Segment | Revenue (USD M) | YOY Growth | Strategic Role |
|---|---|---|---|
| Imaging | 2,552 | +6.6% | Core diagnostic imaging |
| Advanced Visualization Solutions | 1,525 | +5.9% | AI‑driven visualization tools |
| Patient Care Solutions | 825 | -0.3% | Monitoring equipment |
| Pharmaceutical Diagnostics | 790 | +22.3% | Contrast agents and radiopharmaceuticals |
Strategic Developments & Acquisitions
- Completed Acquisitions (2025): Nihon Medi-Physics and icometrix, strengthening radiopharmaceuticals and AI diagnostics
- Planned Acquisition: $2.3 billion purchase of Intelerad (announced Q4), expected to close H1 2026, advancing cloud‑enabled enterprise imaging
- 2026 Guidance: Organic revenue growth projected at 3.0–4.0% YOY; tariff impact expected to be lower than 2025 based on current rates
Market Impact & Commercial Outlook
- Imaging Market Leadership: Strong Imaging growth (+6.6%) reinforces GE HealthCare’s dominant position in the $18 billion global diagnostic imaging market
- Pharmaceutical Diagnostics Surge: 22.3% growth in contrast agents and radiopharmaceuticals driven by rising procedure volumes and new product launches
- Cloud‑Enabled Strategy: Intelerad acquisition positions GE HealthCare to compete with Philips and Siemens Healthineers in enterprise imaging software, a $5 billion annual market
- Revenue Synergies: Analysts project $300–500 million incremental revenue from Intelerad integration by 2027, leveraging GE’s installed base of 4 million+ imaging devices
- Next Steps: Intelerad integration planning to begin Q2 2026; commercial launch of next‑generation AI visualization tools to accelerate Advanced Visualization segment growth
Forward‑Looking Statements
This brief contains forward‑looking statements regarding revenue projections, acquisition timelines, and market growth for GE HealthCare. Actual results may differ due to regulatory approvals, competitive dynamics, and market adoption rates.-Fineline Info & Tech